Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast
Status:
Terminated
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for
their growth. It is not yet known whether surgery is more effective with or without gefitinib
in treating ductal carcinoma in situ.
PURPOSE: This randomized phase II trial is studying how well gefitinib together with surgery
works compared to surgery alone for the treatment of women with ductal carcinoma in situ of
the breast.